CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
Cumberland Pharmaceuticals (NASDAQ: CPIX) has secured a significant contract with Vizient, the nation's largest healthcare performance improvement company, for its new Vibativ® 4-Vial Starter Pak. Vizient serves over 65% of U.S. acute care providers, including 97% of academic medical centers.
Vibativ® is an FDA-approved injectable antibiotic for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin infections caused by Gram-positive pathogens, including MRSA. The drug has demonstrated significantly higher cure rates compared to vancomycin in HABP/VABP cases with specific pathogen profiles.
This contract enhances accessibility to Vibativ's new 4-vial configuration, supporting flexible treatment initiation across inpatient and outpatient settings.
Cumberland Pharmaceuticals (NASDAQ: CPIX) ha ottenuto un importante contratto con Vizient, la più grande azienda nazionale per il miglioramento delle prestazioni sanitarie, per il suo nuovo Starter Pak Vibativ® da 4 fiale. Vizient serve oltre il 65% dei fornitori di cure acute negli Stati Uniti, inclusi il 97% dei centri medici accademici.
Vibativ® è un antibiotico iniettabile approvato dalla FDA per il trattamento della polmonite batterica acquisita in ospedale e associata a ventilatore (HABP/VABP) e delle infezioni cutanee complicate causate da patogeni Gram-positivi, incluso MRSA. Il farmaco ha dimostrato tassi di guarigione significativamente più elevati rispetto alla vancomicina nei casi di HABP/VABP con specifici profili patogeni.
Questo contratto migliora l'accessibilità alla nuova configurazione da 4 fiale di Vibativ, supportando un avvio del trattamento flessibile sia in regime di ricovero che ambulatoriale.
Cumberland Pharmaceuticals (NASDAQ: CPIX) ha asegurado un contrato importante con Vizient, la mayor empresa nacional de mejora del rendimiento sanitario, para su nuevo Starter Pak Vibativ® de 4 viales. Vizient atiende a más del 65% de los proveedores de atención aguda en EE.UU., incluyendo el 97% de los centros médicos académicos.
Vibativ® es un antibiótico inyectable aprobado por la FDA para tratar la neumonía bacteriana adquirida en el hospital y asociada a ventilador (HABP/VABP) y las infecciones cutáneas complicadas causadas por patógenos Gram-positivos, incluido MRSA. El medicamento ha demostrado tasas de curación significativamente más altas en comparación con la vancomicina en casos de HABP/VABP con perfiles patógenos específicos.
Este contrato mejora el acceso a la nueva configuración de 4 viales de Vibativ, apoyando un inicio de tratamiento flexible tanto en entornos hospitalarios como ambulatorios.
Cumberland Pharmaceuticals (NASDAQ: CPIX)는 미국 최대의 의료 성능 개선 회사인 Vizient과 자사의 새로운 Vibativ® 4 바이알 스타터 팩에 대한 중요한 계약을 체결했습니다. Vizient는 미국 급성 치료 제공자의 65% 이상을 포함하여 97%의 학술 의료 센터에 서비스를 제공합니다.
Vibativ®는 병원 획득 및 인공호흡기 관련 세균성 폐렴(HABP/VABP)과 MRSA를 포함한 그람 양성 병원체에 의해 발생하는 복잡한 피부 감염 치료를 위한 FDA 승인 주사 항생제입니다. 이 약물은 특정 병원체 프로필을 가진 HABP/VABP 사례에서 반코마이신 대비 현저히 높은 치료 성공률을 입증했습니다.
이번 계약은 Vibativ의 새로운 4 바이알 구성 접근성을 향상시켜 입원 및 외래 환경 모두에서 유연한 치료 시작을 지원합니다.
Cumberland Pharmaceuticals (NASDAQ : CPIX) a conclu un contrat important avec Vizient, la plus grande entreprise nationale d'amélioration des performances en santé, pour son nouveau Starter Pak Vibativ® de 4 flacons. Vizient dessert plus de 65 % des prestataires de soins aigus aux États-Unis, y compris 97 % des centres médicaux universitaires.
Vibativ® est un antibiotique injectable approuvé par la FDA pour traiter la pneumonie bactérienne nosocomiale et associée au ventilateur (HABP/VABP) ainsi que les infections cutanées compliquées causées par des pathogènes à Gram positif, y compris le MRSA. Le médicament a démontré des taux de guérison significativement plus élevés que la vancomycine dans les cas d'HABP/VABP présentant des profils pathogènes spécifiques.
Ce contrat améliore l'accès à la nouvelle configuration de 4 flacons de Vibativ, soutenant un démarrage flexible du traitement en milieu hospitalier comme en ambulatoire.
Cumberland Pharmaceuticals (NASDAQ: CPIX) hat einen bedeutenden Vertrag mit Vizient, dem größten Gesundheitsleistungsverbesserungsunternehmen des Landes, für sein neues Vibativ® 4-Vial Starterpaket abgeschlossen. Vizient betreut über 65 % der US-amerikanischen Akutversorger, darunter 97 % der akademischen medizinischen Zentren.
Vibativ® ist ein von der FDA zugelassenes injizierbares Antibiotikum zur Behandlung von im Krankenhaus erworbener und beatmungsassoziierter bakterieller Pneumonie (HABP/VABP) sowie komplizierter Hautinfektionen, verursacht durch grampositive Erreger, einschließlich MRSA. Das Medikament hat signifikant höhere Heilungsraten im Vergleich zu Vancomycin bei HABP/VABP-Fällen mit bestimmten Erregerprofilen gezeigt.
Dieser Vertrag verbessert den Zugang zur neuen 4-Vial-Konfiguration von Vibativ und unterstützt einen flexiblen Behandlungsbeginn sowohl in stationären als auch ambulanten Einrichtungen.
- Secured contract with Vizient, reaching over 65% of U.S. acute care providers
- Vibativ shows superior cure rates compared to vancomycin in specific cases
- Expanded market access through both 4-vial and 12-vial configurations
- Product demonstrates broad-spectrum activity against difficult-to-treat pathogens
- Complex safety considerations requiring careful patient monitoring
- Competitive market with existing alternative treatments
Insights
Cumberland secures strategic Vizient contract for Vibativ 4-Vial Starter Pak, expanding distribution to 65% of acute care providers nationwide.
Cumberland Pharmaceuticals has made a significant market access expansion by securing a contract with Vizient for its new Vibativ 4-Vial Starter Pak. This development is strategically important as Vizient is the largest provider-driven healthcare performance improvement company in the U.S., serving over 65% of the nation's acute care providers, including 97% of academic medical centers and 35% of the non-acute market.
The new 4-vial configuration represents a smart product line extension that offers healthcare providers more flexibility in treatment initiation across both inpatient and outpatient settings. This smaller packaging option should help reduce waste and initial inventory costs for facilities, potentially increasing adoption rates among budget-conscious institutions.
Vibativ (telavancin) itself is an important asset in Cumberland's portfolio – it's a potent antibiotic targeting serious Gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The drug has demonstrated clinical advantages over vancomycin in specific patient populations with hospital-acquired and ventilator-associated bacterial pneumonia.
For Cumberland, this agreement represents enhanced market penetration for a key product. The contract with Vizient's extensive provider network should drive increased utilization of Vibativ, potentially boosting revenues in Cumberland's hospital acute care segment. While the financial terms weren't disclosed, the deal strengthens Cumberland's commercial infrastructure by leveraging Vizient's massive distribution network rather than requiring additional internal sales force investment.
Vizient serves more than
Vizient serves more than
"We're pleased to expand availability of the new Vibativ 4-Vial Starter Pak for Vizient-contracted providers, supporting the cost-efficient delivery of our potent antibiotic in hospitals, infusion centers and outpatient centers nationwide," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals.
Vibativ is an FDA-approved injectable antibiotic indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA.
In addition to the Vibativ 4-Vial Starter Pak, the Vibativ 12-vial carton is also available to Vizient provider clients through several distribution channels. For ordering information, please visit www.vibativ.com/order.
For medical questions or educational needs, please contact Cumberland Pharmaceuticals Medical Affairs at MSLsupport@cumberlandpharma.com.
About Vibativ®
Vibativ® (telavancin) injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA. Vibativ is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency, bactericidal activity within six hours and penetration into target infection sites. The drug is approved in the
In addition, Vibativ is approved for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including S. aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling also describes the use of Vibativ in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. The product's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with S. aureus infections studied to date. Importantly, these studies demonstrated significantly higher cure rates for Vibativ as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen or S. aureus with vancomycin MIC ≥1 µg/mL. Additionally, there is extensive and well-documented evidence of the drug's in vitro potency and in vivo activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
For full prescribing information, including important safety information, visit www.vibativ.com.
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has Phase II clinical studies evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy, systemic sclerosis and idiopathic pulmonary fibrosis.
For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, which can be found on the company's website: www.cumberlandpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-receives-vizient-contract-for-new-vibativ-4-vial-starter-pak-302520440.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
What is the significance of Cumberland Pharmaceuticals' Vizient contract for Vibativ?
What conditions does Vibativ (CPIX) treat?
How does Vibativ's efficacy compare to existing treatments?
What are the available configurations for Vibativ through the Vizient contract?
How is Vibativ administered to patients?
